BidaskClub upgraded shares of Fortress Biotech (NASDAQ:FBIO) from a sell rating to a hold rating in a research report report published on Sunday, March 11th.
Other equities analysts have also recently issued reports about the company. HC Wainwright set a $11.00 target price on Fortress Biotech and gave the stock a buy rating in a report on Tuesday, January 2nd. B. Riley initiated coverage on Fortress Biotech in a report on Wednesday, February 28th. They set a buy rating and a $10.00 price target on the stock. ValuEngine raised Fortress Biotech from a sell rating to a hold rating in a report on Thursday, March 1st. Finally, Zacks Investment Research upgraded Fortress Biotech from a sell rating to a hold rating in a research report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $10.80.
Fortress Biotech (FBIO) opened at $5.16 on Friday. Fortress Biotech has a twelve month low of $3.13 and a twelve month high of $5.54. The firm has a market capitalization of $264.93, a price-to-earnings ratio of -3.20 and a beta of 0.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.69 and a current ratio of 2.69.
TRADEMARK VIOLATION NOTICE: This report was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/03/19/fortress-biotech-fbio-upgraded-to-hold-by-bidaskclub.html.
Fortress Biotech Company Profile
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.